Latest Conference

Pedro Cahn, MD, shares the results found after 96-weeks of follow-up for the onceMRK Phase 3 clinical trial.

Jake Glaser describes how recent advances against HIV & AIDS have affected the philanthropic community.

Jake Glaser explains the challenges faced when fundraising for AIDS programs in the 21st century.

Michael Edmond, MD, MPH, MPA, explains how strategies are developed to address different threats in health care settings.

Jake Glaser shares who he feels is going to end the AIDS epidemic.

Jake Glaser shares what is needed to achieve the Fast-Track strategy to end the AIDS epidemic by 2030.

Daniel Diekema, MD, discusses the different roles that clinical laboratories play in outbreak response.

Michael Edmond, MD, MPH, MPA, explains how health care facilities can work on preparing for the unexpected in the realm of infectious diseases.

Daniel Diekema, MD, explains why microbiology labs should be seen as an integral part of antimicrobial stewardship efforts.

James S. Lewis, PharmD, FIDSA, explains how pharmacists can advocate for judicious antibiotic use in patients through educating the patients themselves, as well as providers.

Daniel Diekema, MD, explains how the microbiology lab works to provide optimal drug selection for empiric and directed therapy.

Michael Edmond, MD, MPH, MPA, explains current challenges faced by hospital epidemiologists.

Daniel Diekema, MD, explains why the microbiology laboratory should be a part of antimicrobial stewardship programs.

James S. Lewis, PharmD, FIDSA, explains why addressing issues surrounding antibiotic use in veterinary medicine is crucial in the fight against antibiotic resistance.

Part 3 of our series looks at

David A. Schwartz, MD, MS Hyg, FCAP, notes a topic of interest at the First International Zika Conference.

Another prong in the battle against resistant Gram-negative infections is the addition of beta-lactamase inhibitors to restore or improve the activity of older carbapenems.

Alan Gross, PharmD, discusses testing options for multidrug-resistant pneumonia.

Antimicrobial-resistant organisms, particularly Gram-negative bacteria, present a critical threat and a substantial burden.

Silvio Pitlik, MD, explains why he feels Lyme disease can make individuals obsessive.

In case you missed them, we've compiled the top 5 articles from this past week.

Silvia Munoz-Price, MD, PhD, calls for a clear delineation of the role of hospital epidemiologists.

Alan Gross, PharmD, postulates why one in four patients experienced treatment failure for community-acquired pneumonia in a recent study.

Viviane Boaventura, MD, MsC, PhD, discusses which arbovirus poses the greatest threat to Brazil.

At ID Week 2017, Dr. Laura Cooley, CDC, discussed the increasing number of Legionnaires’ cases in the United States, underscoring the need for stronger water management practices.

Prof. Francisco Veas, PhD, discusses the launch of a task force dedicated to gaining a better understanding of Lyme disease.

Silvia Munoz-Price, MD, PhD, calls for more microbiome research in order to ultimately improve patient care in hospitals.

Brinda Emu, MD, offers insight into the HIV monoclonal antibody ibalizumab.